Literature DB >> 22889722

Risk of nonvertebral fractures among elderly postmenopausal women using antidepressants.

Véronique Rabenda1, Olivier Bruyère, Jean-Yves Reginster.   

Abstract

OBJECTIVE: To examine the association between antidepressants, including TCAs, SSRIs, and miscellaneous antidepressants and the risk of nonvertebral fractures among women with osteoporosis.
MATERIALS AND METHODS: This study was a post-hoc analysis of pooled data from two international, phase III, randomized, placebo-controlled, double-blind studies (the Spinal Osteoporosis Therapeutic Intervention [SOTI] and TReatment Of Peripheral OSteoporosis [TROPOS]). A nested case-control study was performed in the placebo treated population. Adjusted logistic regression models were used to estimate the risk of nonvertebral fracture associated with the use of antidepressants.
RESULTS: After 3 years of follow-up, 391 nonvertebral fractures cases were identified and matched to 1955 controls. Compared with non-users of antidepressants, antidepressants use was associated with an increased risk of nonvertebral fractures (adjusted OR=1.64; 95%CI, 1.03-2.62]). Particularly, there was a 2-fold risk increase (95%CI, 1.07-3.79) of nonvertebral fracture for current users of SSRIs and a 2.1-fold risk increase for subjects who were current users of TCAs (95%CI, 1.02-4.30). Among patients categorized as recent or past users, none of the classes of antidepressants were statistically associated with increased risk of nonvertebral fracture.
CONCLUSIONS: Our findings confirm that both SSRIs and TCAs increase the risk of nonvertebral fracture in current users.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22889722     DOI: 10.1016/j.bone.2012.07.030

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  7 in total

1.  Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.

Authors:  Christoph U Correll; Johan Detraux; Jan De Lepeleire; Marc De Hert
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

2.  Serotonergic antidepressant use and the risk of fracture: a population-based nested case-control study.

Authors:  C-Y Wang; S-H Fu; C-L Wang; P-J Chen; F-L L Wu; F-Y Hsiao
Journal:  Osteoporos Int       Date:  2015-07-01       Impact factor: 4.507

Review 3.  Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome.

Authors:  Olivier Bruyère; Jean-Yves Reginster
Journal:  Endocrine       Date:  2014-08-05       Impact factor: 3.633

4.  Medication use before and after hip fracture: a population-based cohort and case-control study.

Authors:  Maurizio Rossini; Ombretta Viapiana; Silvano Adami; Luca Idolazzi; Stefano Buda; Chiara Veronesi; Luca Degli Esposti; Davide Gatti
Journal:  Drugs Aging       Date:  2014-07       Impact factor: 3.923

Review 5.  Recent advances: osteoporosis in the "oldest old".

Authors:  Cathleen S Colón-Emeric
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

6.  Patterns of selective serotonin reuptake inhibitor use and risk of falls and fractures in community-dwelling elderly people: the Three-City cohort.

Authors:  I Carrière; A Farré; J Norton; M Wyart; C Tzourio; P Noize; K Pérès; A Fourrier-Réglat; M L Ancelin
Journal:  Osteoporos Int       Date:  2016-06-16       Impact factor: 4.507

7.  Medication monitoring for people with dementia in care homes: the feasibility and clinical impact of nurse-led monitoring.

Authors:  Sue Jordan; Marie Gabe; Louise Newson; Sherrill Snelgrove; Gerwyn Panes; Aldo Picek; Ian T Russell; Michael Dennis
Journal:  ScientificWorldJournal       Date:  2014-02-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.